Abstract
Axial spondyloarthritis (axSpA) is a systemic inflammatory disease that can significantly contribute to the deterioration ofthe quality of life. That is why nowadays the emphasis is ptaced on early diagnosis and initiation of treatment.
Ixekizumab is an inhibitor of interleukin (IL)-17A, which has shown good efficacy with long-term efficacy in patients with a radiographicform ofthe disease (r-axSpA) who were naivě to the use of biological treatment, in patients treated with tumor necrosis factor inhibitors (TNFi), and in non-radiographic (nr-axSpA) patients. In addition, current three-year follow-up data from the COAST studies did not show significant changes in the safety profile compared to previously reported adverse events.
In addition, 89.6% of patients with r-axSpA had stable radiographic findings after 2 years,